Clinical Trial

Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children

Recruiting
View on ClinicalTrials.gov →
Summary
Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper respiratory tract infections (URTIs) in a healthy paediatric population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-27.
Trial Details
NCT Number NCT07154992
Lead Sponsor Bioithas SL
Collaborators: Centro Sperimentale del Latte S.r.l.
Conditions Upper Respiratory Tract Infection, Prevention
Enrollment 268 participants
Start Date 2024-12-17
Primary Completion 2027-03 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-09-12